A trafficking regulatory subnetwork governs αVβ6 integrin-HER2 cross-talk to control breast cancer invasion and drug resistance

Maldonado, Horacio; Dreger, Marcel; Bedgood, Lara D.; Kyriakou, Theano; Wolanska, Katarzyna I.; Rigby, Megan E.; Marotta, Valeria E.; Webster, Justine M.; Wang, Jun; Rusilowicz-Jones, Emma V.; Marshall, John F.; Coulson, Judy M.; Macpherson, Iain R.; Hurlstone, Adam; Morgan, Mark R.

Abstract

HER2 and alpha V beta 6 integrin are independent predictors of breast cancer survival and metastasis. We identify an alpha V beta 6/HER2 cross-talk mechanism driving invasion, which is dysregulated in drug-resistant HER2+ breast cancer cells. Proteomic analyses reveal ligand-bound alpha V beta 6 recruits HER2 and a trafficking subnetwork, comprising guanosine triphosphatases RAB5 and RAB7A and the Rab regulator guanine nucleotide dissociation inhibitor 2 (GDI2). The RAB5/RAB7A/GDI2 functional module mediates direct cross-talk between alpha V beta 6 and HER2, affecting receptor trafficking and signaling. Acute exposure to trastuzumab increases recruitment of the subnetwork to alpha V beta 6, but trastuzumab resistance decouples GDI2 recruitment. GDI2, RAB5, and RAB7A cooperate to regulate migration and transforming growth factor-beta activation to promote invasion. However, these mechanisms are dysregulated in trastuzumab-resistant cells. In patients, RAB5A, RAB7A, and GDI2 expression correlates with patient survival and alpha V beta 6 expression predicts relapse following trastuzumab treatment. Thus, the RAB5/RAB7A/GDI2 subnetwork regulates alpha V beta 6-HER2 cross-talk to drive breast cancer invasion but is subverted in trastuzumab-resistant cells to drive alpha V beta 6-independent and HER2-independent tumor progression.

Más información

Título según WOS: ID WOS:001370044900017 Not found in local WOS DB
Título de la Revista: SCIENCE ADVANCES
Volumen: 10
Número: 49
Editorial: AMER ASSOC ADVANCEMENT SCIENCE
Fecha de publicación: 2024
DOI:

10.1126/sciadv.adk9944

Notas: ISI